AI Engines For more Details: Perplexity Kagi Labs You
Menstrual Disorders: Dydrogesterone is commonly prescribed to treat menstrual disorders such as irregular menstruation, dysmenorrhea (painful menstruation), and heavy menstrual bleeding.
Endometriosis: Dydrogesterone is used to manage endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus, causing pain and infertility.
Infertility: Dydrogesterone is sometimes used as part of fertility treatment protocols to support embryo implantation and early pregnancy in women undergoing assisted reproductive techniques such as in vitro fertilization (IVF).
Premenstrual Syndrome (PMS): Dydrogesterone may be prescribed to alleviate symptoms associated with PMS, such as mood swings, irritability, breast tenderness, and bloating.
Hormone Replacement Therapy (HRT): In postmenopausal women, dydrogesterone can be used as part of hormone replacement therapy to relieve menopausal symptoms and prevent osteoporosis.
Threatened or Recurrent Miscarriage: Dydrogesterone may be prescribed to reduce the risk of miscarriage in women with a history of recurrent miscarriages or in cases of threatened miscarriage.
Prevention of Endometrial Hyperplasia: In women receiving estrogen replacement therapy (ERT), dydrogesterone can be used to prevent endometrial hyperplasia, a precancerous condition of the uterine lining, which may occur due to unopposed estrogen stimulation.
Breast Disorders: Dydrogesterone has also been investigated for the treatment of certain breast disorders, although its use for this purpose is less common.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Akkermansiaceae | family | Decreases |
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Ruminococcus | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Fusobacterium | genus | Decreases |
| 0 | 1 | Lachnospira | genus | Decreases |
| 0 | 1 | Lacrimispora | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 1 | 0 | Akkermansia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 0 | 1 | environmental samples | no rank | Decreases |
| 0 | 1 | unclassified Akkermansia | no rank | Decreases |
| 1 | 0 | Roseburia hominis | species | Decreases |
| 1 | 0 | Ruminococcus bromii | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 0 | 1 | Akkermansia massiliensis | species | Decreases |
| 0 | 1 | Candidatus Akkermansia intestinavium | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Lachnospira eligens | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Lacrimispora saccharolytica | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Fusobacterium nucleatum | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Akkermansia muciniphila | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | [Ruminococcus] torques | species | Decreases |
| 0 | 1 | Akkermansia glycaniphila | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Fusobacterium nucleatum subsp. nucleatum | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0 | 0 |
| ADHD | 2.2 | 2.2 | |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 1.3 | 0 | 0 |
| Allergies | 1.6 | 1.5 | 0.07 |
| Allergy to milk products | 0.7 | 0.7 | 0 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 2.8 | 3.1 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.3 | 0.4 | 2.25 |
| Ankylosing spondylitis | 1.3 | 1.2 | 0.08 |
| Anorexia Nervosa | 0.7 | 2.1 | -2 |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 2.4 | 0.9 | 1.67 |
| Atherosclerosis | 1 | 0.8 | 0.25 |
| Atrial fibrillation | 2.3 | 1.2 | 0.92 |
| Autism | 3 | 4 | -0.33 |
| Autoimmune Disease | 0.5 | -0.5 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 1.3 | 0.8 | 0.63 |
| Brain Trauma | 1.1 | -1.1 | |
| Breast Cancer | 0.1 | 0.3 | -2 |
| Cancer (General) | 0.6 | 0.2 | 2 |
| Carcinoma | 2.5 | 1.9 | 0.32 |
| Celiac Disease | 0.7 | 2.5 | -2.57 |
| Cerebral Palsy | 0.3 | 1.1 | -2.67 |
| Chronic Fatigue Syndrome | 1.4 | 2.1 | -0.5 |
| Chronic Kidney Disease | 1.3 | 1.4 | -0.08 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 1.1 | -2.67 |
| Chronic Urticaria (Hives) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.8 | -1 |
| Cognitive Function | 2.1 | 0.8 | 1.63 |
| Colorectal Cancer | 3.7 | 1.4 | 1.64 |
| Constipation | 0.9 | 0.5 | 0.8 |
| Coronary artery disease | 0.6 | 1.5 | -1.5 |
| COVID-19 | 2.1 | 3.6 | -0.71 |
| Crohn's Disease | 3.4 | 3.6 | -0.06 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 1.1 | 1.1 | 0 |
| Denture Wearers Oral Shifts | 0.1 | 0.1 | |
| Depression | 4.4 | 4.4 | 0 |
| Eczema | 0.3 | 0.1 | 2 |
| Endometriosis | 1.3 | 1.4 | -0.08 |
| Eosinophilic Esophagitis | 0.3 | 0.3 | |
| Epilepsy | 0.7 | 0.8 | -0.14 |
| erectile dysfunction | 0.6 | 0.6 | |
| Fibromyalgia | 1.6 | 0.3 | 4.33 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 1.7 | 0.06 |
| gallstone disease (gsd) | 1.4 | 0.9 | 0.56 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | 0.3 | 0.67 |
| Generalized anxiety disorder | 0.6 | 0.9 | -0.5 |
| Gout | 0.6 | 0.3 | 1 |
| Graves' disease | 1 | 1.7 | -0.7 |
| Gulf War Syndrome | 0.2 | -0.2 | |
| Halitosis | 0.7 | 0.7 | |
| Hashimoto's thyroiditis | 2.2 | 0.9 | 1.44 |
| Heart Failure | 1.3 | 1.1 | 0.18 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.2 | 1.2 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
| hyperglycemia | 0.6 | 0.8 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 2 | 2.7 | -0.35 |
| Hypothyroidism | 0 | 0 | |
| Hypoxia | 1.3 | 1.3 | |
| IgA nephropathy (IgAN) | 1.3 | 0.8 | 0.63 |
| Inflammatory Bowel Disease | 1.9 | 3.4 | -0.79 |
| Insomnia | 0.9 | 1.8 | -1 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 1.3 | 1.3 | |
| Irritable Bowel Syndrome | 2.1 | 2 | 0.05 |
| ischemic stroke | 1.1 | 1.1 | 0 |
| Liver Cirrhosis | 4.1 | 3 | 0.37 |
| Long COVID | 1.9 | 4.3 | -1.26 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.3 | 1 | -2.33 |
| Mast Cell Issues / mastitis | 0.1 | 0.3 | -2 |
| ME/CFS with IBS | 0.7 | -0.7 | |
| ME/CFS without IBS | 1.4 | -1.4 | |
| Menopause | 0.6 | -0.6 | |
| Metabolic Syndrome | 3.3 | 3.9 | -0.18 |
| Mood Disorders | 3.9 | 2.6 | 0.5 |
| multiple chemical sensitivity [MCS] | 0 | 0 | |
| Multiple Sclerosis | 2 | 2.6 | -0.3 |
| Multiple system atrophy (MSA) | 0.7 | 0.3 | 1.33 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 2.4 | -2.4 | |
| Neuropathy (all types) | 0 | 1.1 | 0 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 2 | 0.3 |
| NonCeliac Gluten Sensitivity | 0.4 | 0.3 | 0.33 |
| Obesity | 5.3 | 4.1 | 0.29 |
| obsessive-compulsive disorder | 1.7 | 1.5 | 0.13 |
| Osteoarthritis | 0.3 | 0.6 | -1 |
| Osteoporosis | 1.1 | 0.9 | 0.22 |
| pancreatic cancer | 0.4 | 0.4 | |
| Parkinson's Disease | 3.2 | 3 | 0.07 |
| Polycystic ovary syndrome | 2.6 | 2.2 | 0.18 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.6 | 0.3 | 1 |
| Primary sclerosing cholangitis | 1 | 0.8 | 0.25 |
| Psoriasis | 0.9 | 1.6 | -0.78 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 3.7 | 2.3 | 0.61 |
| Rosacea | 0.3 | 0.5 | -0.67 |
| Schizophrenia | 2.3 | 1.9 | 0.21 |
| scoliosis | 0.8 | -0.8 | |
| Sjögren syndrome | 0.7 | 1.6 | -1.29 |
| Sleep Apnea | 1.5 | 1.1 | 0.36 |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 2.2 | 1.3 | 0.69 |
| Systemic Lupus Erythematosus | 1.7 | 1.5 | 0.13 |
| Tic Disorder | 0.6 | 0.6 | 0 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 1.1 | 1.4 | -0.27 |
| Type 2 Diabetes | 3.8 | 2.8 | 0.36 |
| Ulcerative colitis | 1.8 | 3.1 | -0.72 |
| Unhealthy Ageing | 1.7 | 1.5 | 0.13 |
| Vitiligo | 1.4 | 0.5 | 1.8 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
